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Background: Early induction with biologics can reduce complications in patients with Crohn’s disease (CD) and
improve their quality of life. The safety of biologics, however, is uncertain. Granulocyte and monocyte adsorptive
apheresis (GMAA) is a natural biologic therapy that selectively removes granulocytes and monocytes/macrophages
and has few severe adverse effects. The effects of GMAA on patients with early-diagnosed CD are unclear. We
investigated the effects of GMAA combined with thiopurines on patients with early-diagnosed CD.
Methods: Twenty-two corticosteroid- and biologic-naïve patients with active early-diagnosed CD were treated with
intensive GMAA (twice per week) combined with thiopurines administration. Active early-diagnosed CD was defined
as follows: (i) within 2years after diagnosis of CD, (ii) with no history of both surgical treatment and endoscopic
dilation therapy, and (iii) Crohn’s Disease Activity Index (CDAI) was higher than 200. We investigated the ratios of
clinical remission defined as CDAI was less than or equal to 150 at 2, 4, 6 and 52weeks and mucosal healing defined
as a Simplified Endoscopic Activity Score for Crohn’s Disease (SES-CD) as 0 at 6 and 52weeks. Adverse events were
recorded at each visit.
Results: The ratios of clinical remission at 2, 4, and 6 weeks were 6 of 22 (27.2%), 12 of 22 (54.5%), and 17 of 22
(77.2%), respectively. At 52 weeks, 18 of 21 patients (81.8%) were in clinical remission. The ratios of mucosal healing
at 6 and 52 weeks were 5 of 22 (22.7%) and 11 of 22 (50%), respectively. The difference in the mucosal healing ratio
was significant between 6 and 52 weeks (p = 0.044). No serious adverse effects were observed during this study.
Conclusions: Combination therapy with intensive GMAA and thiopurines administration rapidly induced high
remission in patients with active early-diagnosed CD without serious adverse effect. Mucosal healing was observed
in 50.0% of enrolled patients. This combination therapy might be a rational option for patients with early-diagnosed
CD.
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Crohn’s disease (CD) is a chronic inflammatory disorder
of unknown etiology. The current practice guidelines are
designed to maintain remission with optimal medication
after induction therapy due to the potential for repeated
relapse in patients with CD [1,2].
Corticosteroids effectively suppress acute CD flares.
Approximately 60% of patients will have a complete re-
sponse during the short-term outcome (30 days) of a
first course of steroids [3]. Long-term exposure to corti-
costeroids, however, is problematic due to dependency
and/or the development of resistance [4].
In the last 15 years, the advent of biologic therapies,
such as anti-tumor necrosis factor (TNF)-α, has improved
the management of refractory CD. In addition, the efficacy
of TNF-α antagonists suggests a new concept that early
induction with intensive therapy may reduce complica-
tions associated with conventional treatment and improve
the patient’s quality of life [5]. In this regard, intensive
therapy with early use of this biologic agent has been pro-
posed and is known as ‘top-down’ therapy. Early use of
anti-TNF therapy, however, is associated with the develop-
ment of serious life-threatening infections in addition to
other well-documented hematologic, immunologic, car-
diovascular, and malignant adverse effects [6]. Therefore,
whether long-term use of anti-TNF therapy is suitable for
all patients with CD remains unclear.
A 2-year open-label randomized trial by D’Haens et al.
[5] showed that short-term infliximab (IFX) combined
with azathioprine (AZA) or 6-mercaptopurine was more
effective than conventional management for the induction
of remission and reduction of corticosteroid use in pa-
tients recently diagnosed with CD, and patients treated
with early combined immunosuppression had consistently
higher rates of remission than controls within the first
year of treatment. The findings from this study suggest
that early use of immunomodulators following optimal in-
duction therapies has favorable effects on active CD. In
addition, recent Hungarian population-based inception
cohort [7] showed that a reduction in the surgical ratio in
patients with CD was independently associated with in-
creased early use of thiopurines. Thus, the development of
promising induction therapies with thiopurines is ex-
pected for patients with CD to avoid complications related
to various drugs as much as possible.
The therapeutic effects and safety of granulocyte
and monocyte adsorptive apheresis (GMAA) with the
Adacolumn (JIMRO, Takasaki, Gunma, Japan) for pa-
tients with inflammatory bowel disease (IBD) have been
much focused because this system can be expected to be
a natural biologic therapy in that selectively removing
granulocytes and monocytes/macrophages from the per-
ipheral blood leads to decreased production of inflam-
matory cytokines [8-10]. Recent data demonstrated thatulcerative colitis (UC) patients treated with a twice-a-
week regimen (intensive GMAA) could achieve sig-
nificantly higher ratios of clinical remission and mucosal
healing compared with an once-a-week regimen (weekly
GMAA) [11,12]. In addition, it was reported that thera-
peutic effect of GMAA with 10 sessions on active UC
patients was superior to that with 5 sessions [13,14].
Thus, intensive GMAA with 10 sessions might be an op-
timal therapy for the induction of remission in patients
with CD as well as UC.
In the present study, we prospectively followed patients
with newly diagnosed CD for 1year after administering in-
tensive GMAA combined with thiopurines, focusing on
clinical remission and endoscopic activity.
Methods
Patients
From January 2010 to August 2012, a total of 22 cortico-
steroid- and biologics-naïve patients with moderate to
severe active early-diagnosed CD were enrolled in the
study. Early-diagnosed CD was defined as follows: (i)
diagnosis within the past 2years, (ii) patients with CD
and a past history of surgery and endoscopic dilation for
CD were excluded. The diagnosis of CD was based on
clinical, endoscopic, radiologic, and histologic findings.
Fecal bacteria culture yielded no specific pathogens in
any of the patients. Patients older than 17 years of age
with active early-diagnosed CD were consecutively re-
cruited if they had newly or relapsing active disease.
Moderate-to-severe active CD was defined as a Crohn’s
Disease Activity Index (CDAI) [15] higher than 200.
Oral aminosalicylates were only permitted if given at a
stable dose. None of the patients had undergone pre-
vious treatment with corticosteroids or TNF-α anta-
gonists (Table 1).
Treatment
All 22 patients with early-diagnosed CD were treated by
GMAA combined with thiopurine administration. Inten-
sive GMAA treatment (twice per week, 10 sessions) was
performed as previously described [11,12,16] for all pa-
tients with CD. Blood was accessed via the antecubital
vein in one arm, and from the outflow blood was returned
to patients via the antecubital vein in the other arm
through 19 gauge needles. The apheresis session was per-
formed at a flow rate 30 mL/min for 60 min, aiming to ex-
pose 1800 mL blood/session. Anti-coagulation for GMAA
therapy was induced by heparin sodium. Thiopurines were
administered to all 22 patients at the start of GMAA ther-
apy. The dose of thiopurines was adjusted to aim for a
white blood cell count < 5000/ml. Patients responding to
treatment with intensive GMAA kept receiving thio-
purines drugs for 52 weeks from the end of the intensive
GMAA. Mean daily dose of thiopurines was 30.0 ±
Table 1 Clinical parameters of patients with early-diagnosed
Crohn’s disease treated by intensive granulocyte and
monocyte adsorptive apheresis combined with thiopurines
therapy
Age (years) 39.5 ± 2.9
Sex (men/women) 18/4















CDAI 260.0 ± 10.5
SES-CD 9.4 ± 0.9
CRP (mg/dl) 3.5 ± 0.7
Number of patients is shown for sex, disease location, disease behavior,
perianal disease and previous treatment. Data are presented as mean ± SE for
age, disease duration, CDAI, SES-CD, and CRP. 5-ASA 5-aminosalicylate; CDAI,
Crohn’s disease activity index; SES-CD, Simple endoscopic score of Crohn’s
disease. Values in parenthesis on vertical line are percentages of all 22 patients
with early-diagnosed CD.
Fukuchi et al. BMC Gastroenterology 2014, 14:124 Page 3 of 7
http://www.biomedcentral.com/1471-230X/14/1242.5 mg. During this study, adverse events were recorded at
each visit.
The protocol and patients’ informed consent forms
were reviewed and approved by the Institutional Review
Board at Osakafu Saiseikai Nakatsu Hospital. The study
was conducted in accordance with the Declaration of
Helsinki, the consolidated Good Clinical Practice Guide-
lines, and the applicable regulatory requirements.
Assessment of endoscopic severity
All 22 patients with early-diagnosed CD underwent ileo-
colonoscopic examinations before, and at 6 and 52 weeks
after treatment. Endoscopic severity of CD was assessed
using the Simplified Endoscopic Activity Score for Crohn’s
Disease (SES-CD) [17].
Assessment
Primary efficacy was evaluated based on the clinical remis-
sion rate at 2, 4, and 6weeks during intensive GMAA, and
13, 26, and 52weeks after starting treatment. Clinical re-
mission was defined as CDAI ≤ 150. Secondary efficacywas evaluated based on SES-CD, complete mucosal heal-
ing rate, and mean C-reactive protein (CRP) values at
weeks 6 and 52. Complete mucosal healing was defined as
a SES-CD of 0 [18]. If patients received rescue treatment
such as intensive GMAA again, corticosteroids, or bio-
logics because of clinical relapse of CD, their treatment
was considered to have failed.
Statistical analysis
Data are presented as mean ± SE. Categorical and con-
tinuous data were compared using a two-tailed Fisher
exact test and Student’s t-test. A p value of less than
0.05 was considered statistically significant.
Results
Clinical characteristics
The clinical characteristics of patients with early-diag-
nosed CD enrolled in this study are summarized in
Table 1. Mean patient age was 39.5 ± 2.9 years, mean pa-
tient disease duration was 5.8 ± 1.8 months (range 1–32
months), and mean CDAI was 260.0 ± 10.5. Disease loca-
tion was the colon in 13 (59.1%), colon/ileum in 3
(13.6%), and ileum in 6 (27.3%). Mean SES-CD was
9.4 ± 0.9 (range 5–19). Of the 22 patients, 5 patients
(22.7%) were treated with a stable dose (3000 mg) of
5-ASA. None of patients enrolled in the study had been
treated previously with corticosteroids, thiopurines, or
biologics (Table 1).
Clinical efficacy
The ratios of clinical remission at 2, 4, and 6weeks were
6 of 22 (27.2%), 12 of 22 (54.5%), and 17 of 22 (77.2%),
respectively (Figure 1). Mean time and number of
GMAA sessions to clinical remission were 28.0 ± 2.9 days
and 7.3 ± 0.6 sessions, respectively, in patients with CD
who achieved clinical remission during intensive GMAA.
One patient with colonic structure and 1 of 2 patients
with perianal disease did not achieve clinical remission
during intensive GMAA. The ratios of clinical remission
at 13weeks and 26weeks were 18 of 22 (81.8%) and 19 of
22 patients (86.4%), respectively. At 52 weeks, 18 of 22
patients (81.8%) were in clinical remission (Figure 1).
During this study, two patients were treated with ada-
limumab because of non-response to intensive GMAA
and two patients required intensive GMAA again
because of CD flares.
Evaluation of mucosal healing
Mean SES-CD scores in all patients are shown in
Figure 2-A. Mean SES-CD scores were compared at three
time points (0, 6, and 52weeks). The scores were signifi-
cantly different between 0 and 52weeks. In addition, the
ratios of mucosal healing at 6 and 52weeks were 5 of 22
(22.7%) and 11 of 22 (50%), respectively (Figure 2-B). The
Figure 1 Maintenance of clinical remission and response in patients responding to combination therapy with intensive GMAA and
thiopurines. Bar graph showing the percentage of patients in remission (CDAI < 150) over time.
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Change in CRP values by treatment
At 6weeks after starting treatment, the mean CRP for all
patients decreased significantly from 3.5 ± 0.7 to 0.4 ±
0.1mg/dl (p = 0.00003). At 52weeks, mean CRP in pa-
tients followed for 52weeks was 0.2 ± 0.1 mg/dl. Serum
CRP levels differed significantly between before treat-
ment and 52weeks (p = 0.0002).
Safety
Two patients complained of nausea, but their symptoms
improved following a dose reduction of thiopurines. NoFigure 2 The change of endoscopic findings in the patients with early
intensive GMAA and thiopurines. (A) Bar graph illustrating the mean Ac
mucosal healing at 6 and 52 weeks after starting treatment.other serious adverse effects were observed during this
study.
Discussion
In the present study we firstly demonstrated that inten-
sive GMAA in combination with thiopurines resulted in
higher ratios of clinical remission and mucosal healing
at 52weeks in corticosteroid- and biologics-naïve pa-
tients with early-diagnosed CD. This clinical study was
of small size, however, expected to demonstrate the effi-
cacy and safety of the combination therapy of GMAA
and thiopurines.
The Study of Biologic and Immunomodulator Naïve
Patients in Crohn’s Disease (SONIC) demonstrated that-diagnosed Crohn’s disease by combination therapy with
tivity Score for Crohn’s Disease (SES-CD) scores and (B) the ratio of
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therapy for patients not treated previously with AZA [19].
An open-labeled clinical trial reported by D’Haens et al.
[5] showed the combination therapy (immunomodulators
in combination with three infusions of IFX at 0, 2, and
6 weeks) resulted in a significantly higher clinical remis-
sion rate in patients with early-diagnosed CD compared
with conventional medication. These data suggest the im-
portance of optimal induction therapies with thiopurines
for patients with early-diagnosed CD.
In this study, we performed intensive GMAA (twice per
week) as an alternative to weekly GMAA as an induction
therapy. Previous data on the ratios of the induction of
remission in active CD refractory to corticosteroids by
weekly GMAA vary (30%-60%) [20-22]. Thus, the efficacy
of GMAA therapy on active CD patients as an induction
therapy has not been established. On the contrary, the re-
markable usefulness of intensive GMAA for the induction
of remission and mucosal healing in patients with active
UC compared with weekly GMAA suggests that the
therapeutic effects of GMAA are associated with fre-
quency of therapy per week [11,12]. In fact, our data
showed that this combination therapy as an induction
treatment in patients with active CD showed a remission
rate comparable to that of corticosteroids or biologics
reported in controlled trials [3,5,19]. The therapeutic out-
come of intensive GMAA in this study might be due to
not only the GMAA frequency per week, but also the
population of eligible patients (corticosteroid- and bio-
logics-naïve early-diagnosed CD). In this regard, intensive
GMAA with thiopurines can be a promising induction
therapy for patients with early-diagnosed CD. Additio-
nally, there were no adverse effects related to GMAA in
this study. The induction of remission by GMAA in the
patients with early-diagnosed CD would have the advan-
tage in the point of avoiding adverse effects related to cor-
ticosteroid and biologics.
Several studies have demonstrated the efficacy of im-
munomodulators to prevent relapse in patients with CD
and showed that early use of immunomodulators de-
creases the cumulative surgical rate in patients with CD
[5,7,23]. In the present study, maintenance treatment
with thiopurines increased the clinical remission rate in
patients with early-diagnosed CD after treatment with
intensive GMAA. Also, our data demonstrated an ex-
tremely high clinical remission rate at 52 weeks (81.8%)
in CD patients treated with combination therapy in
comparison with previous reports. In this regard, the dif-
ference in the number and characteristics of the enrolled
patients may account for the differences in the clinical
remission ratio between the present study and previous
data. In this study, how treatment with thiopurines
could involve in having CD patients keep remission re-
mains unclear. Therefore, future clinical trial comparingthe relapse-free survival of CD patients achieving remis-
sion by GMAA who receive thopurines with those who
do not, should be required. This head to head trial might
elucidate who requires thiopurines among patients with
early-diagnosed CD achieved clinical remission after
GMAA.
It should be noted that recent two clinical trials demon-
strated that very early administration of AZA is not effec-
tive for corticosteroid free-clinical remission in patients
with newly diagnosed CD [24,25]. However, one trial (the
GETAID group) showed that approximately 60% of CD
patients in the conventional management group finally re-
quired any immunosuppressive drugs for corticosteroid
free-clinical remission in a 3-year study period and the
occurrence of perianal lesions was significantly lower in
the AZA-treated group than in the conventionally-treated
group [24]. In addition, another trial (the AZTEC study
group) reported that early AZA therapy is more effective
for preventing a moderate to severe relapse in a post hoc
analysis [25]. Thus, these two reports did not necessarily
deny the effect of AZA in the treatment for CD patients
[24,25], but we should realize that these two clinical trials
suggest the importance of identifying when AZA would
be started in the population of CD patients whose disease
activity becomes progressive without optimal immuno-
suppressive treatments.
Recently, mucosal healing has been focused as a pre-
dictive marker of sustained remission irrespective of no
demonstration of clinical benefit of achieving complete
mucosal healing [18,26,27]. Rutgeerts et al. [26] reported
the value of an endoscopic score to predict recurrent CD.
In addition, Baert et al. [18] demonstrated the importance
of mucosal healing defined as SES-CD 0, based on a sig-
nificant difference in the steroid-free remission ratio after
therapy between patients with CD with SES-CD 0 and
SES-CD 1–9. In the present study, we prospectively exa-
mined mucosal healing in patients with CD treated with
combination therapy. We observed that ratios of mucosal
healing at 6 and 52 weeks were 22.7% and 50.0%, res-
pectively, and that at 52 weeks was comparable to data
reported by D’Haens et al. [27] and Colombel et al. [19].
Thus, our and D’Haens et al. [27] data might suggest
the usefulness of early induction with thiopurines in
biologics-naive patients with CD after induction with
optimal therapy, such as intensive GMAA, although we
should consider that the timing of the evaluation of muco-
sal healing varied depending on the medical treatment
and the characteristics of the enrolled patients.
The overall incidence of adverse events was related to
thiopurines, and not intensive GMAA. It was reported
that the combination of thiopurines and anti-TNF biologic
agents increases the relative risk of serious and opportu-
nistic infections [28]. Also, the use of corticosteroids may
further increase the relative risk of infections [3]. GMAA
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has few severe adverse effects. In the point of avoiding ser-
ious side effect and being performed repeatedly and safely,
GMAA might be more advantageous than anti-TNF or
corticosteroids. Therefore, intensive GMAA is considered
to be an induction therapy alternative to corticosteroids
and three infusions of IFX (at 0, 2, and 6 weeks).
Conclusions
Our findings showed that the combination therapy with
intensive GMAA and thiopurines was an effective and
well-tolerated therapeutic option for inducing and main-
taining clinical remission in patients with early-diagnosed
CD. The data, however, were derived from an open study
including only a small number of patients, and did not ad-
dress whether intensive GMAA with thiopurines for
biologics-naïve patients with early-diagnosed CD was
superior to corticosteroids and IFX. Therefore, future pro-
spective studies with larger numbers of patients are re-
quired to assess the efficacy and safety of this combination
therapy.
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